Reported Earlier, HUTCHMED Closes Exclusive License Of KRAS-EGFR ATTC HMPL-A830 To GSK Outside China, Expects $110M Upfront Payment And Up To $1.185B In Milestones

Loading news article.

Reported Earlier, HUTCHMED Closes Exclusive License Of KRAS-EGFR ATTC HMPL-A830 To GSK Outside China, Expects $110M Upfront Payment And Up To $1.185B In Milestones | WAPE

Reported Earlier, HUTCHMED Closes Exclusive License Of KRAS-EGFR ATTC HMPL-A830 To GSK Outside China, Expects $110M Upfront Payment And Up To $1.185B In Milestones

Article summary

Related companies

Comments —